Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 712 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Completed No phase listed Observational

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

NCT03936335
View directory record Official record
Conditions
Adverse Pregnancy Outcomes, Atopic Dermatitis
Interventions
dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
12,343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

NCT03750643
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
LY3454738, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
19
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Rogers, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness

NCT02148796
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Broncho-Vaxom (BV), Placebo
Drug · Other
Lead sponsor
University of Arizona
Other
Eligibility
6 Months to 18 Months
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
11
States / cities
Phoenix, Arizona • Tucson, Arizona • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 4 Interventional

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

NCT01202149
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Device
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Dupilumab Skin Barrier Function Study in Atopic Dermatitis

NCT04447417
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab SAR231893
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

DMT210 Topical Gel in the Treatment of Atopic Dermatitis

NCT02949960
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DMT210 Topical Gel, Vehicle Control
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Houston, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1 Interventional

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis

NCT01678092
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
omalizumab
Biological
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 25 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 30, 2026, 1:23 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

NCT03819881
View directory record Official record
Conditions
Atopic Immunoglobulin E-Mediated Allergic Disorder
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
2 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Stockton, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional Results available

Acupressure in Pruritus for Atopic Dermatitis

NCT01074164
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Standard-of-care treatment for AD, Accu-patch pellet
Other · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 30, 2026, 1:23 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis

NCT02286700
View directory record Official record
Conditions
Dermatitis, Atopic, Eczema
Interventions
Desonide Cream, Amino Acid Moisturizing Cream
Drug · Other
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2014 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

NCT05372419
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
36
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Dose-ranging Study of Nemolizumab in Atopic Dermatitis

NCT03100344
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational

Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

NCT04404075
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
SkinTracker Mobile App
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years and older
Enrollment
11 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

NCT02950922
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.2% ointment, RVT-501 0.5% ointment, Vehicle ointment
Drug · Other
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
12 Years to 70 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 30, 2026, 1:23 PM EDT
Recruiting Phase 1 Interventional

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT07262983
View directory record Official record
Conditions
Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome, HIES, Lupus, Atopic Dermatitis
Interventions
baricitinib
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

NCT03745651
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Fremont, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD Study

NCT05131477
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Fremont, California • Sacramento, California • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

NCT07765888
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 2 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

NCT02525094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
MEDI9929, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
8
States / cities
North Miami Beach, Florida • Tampa, Florida • Arlington Hts, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 30, 2026, 1:23 PM EDT
Not listed Phase 1 Interventional

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

NCT03415282
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RVT-501 0.5% topical ointment
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
12
States / cities
Anniston, Alabama • Irvine, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 30, 2026, 1:23 PM EDT
Withdrawn Not applicable Interventional

Tencel vs. Standard Cotton Therapeutic Garments as an Adjunct Treatment for Moderate to Severe Atopic Dermatitis in Children

NCT03843437
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tencel Therapeutic Garments, Cotton Therapeutic Garments
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Months to 6 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Emollient Therapy on the Skin Barrier

NCT01291940
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Pediatric Moisturizer, Adult Moisturizer
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Months to 99 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 30, 2026, 1:23 PM EDT